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Background: Limited successes of conventional approaches to type 1 diabetes (T1D) prevention and treatment have highlighted the need for
improved understanding of risk factors contributing to or hastening progression to clinical diagnosis.
Scope of review: This review summarizes beta cell function metabolic phenotyping data from clinical studies conducted in at-risk individuals
before T1D onset and healthy controls. Data are drawn from studies comparing at-risk individuals who progress to T1D to at-risk individuals who
do not progress to T1D, as well as from studies comparing at-risk individuals to controls without a T1D family history.
Major conclusions: Rapid loss of beta cell insulin secretion occurs in the months immediately preceding clinical onset. However, evidence of
beta cell dysfunction is present even years earlier. Comparisons to controls without a family history suggest that many individuals in families
impacted by T1D have evidence of beta cell dysfunction, even individuals who are unlikely to develop clinical disease. These findings may mean
that underlying metabolic beta cell dysfunction contributes to T1D development and may explain some of the heterogeneity observed in the
disease.
 2019 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The incidence of Type 1 Diabetes Mellitus (T1D) is rising at a rate of
nearly 3% per year; and the disease constitutes billions of dollars of
annual healthcare expenditures [1e4]. Furthermore, despite improved
formulations of insulin and improved technologies for glucose moni-
toring and insulin administration, most persons with T1D do not
achieve the glycemic control recommended to avoid acute and chronic
diabetes-associated complications [5]. These statistics highlight the
need for effective T1D prevention and treatment strategies. Although
T1D is classically defined as autoimmune destruction of the pancreatic
beta cells, immunomodulatory interventions alone have been unable to
produce durable disease remissions [6e11]. There are multiple rea-
sons for the limited successes of these interventions e including
heterogeneity of clinical disease, initiation of therapies at later stages
of disease, and a need for repeated dosing [11,12]. Additionally,
effective T1D prevention or treatment will likely require combination
therapies of agents targeting multiple pathologic mechanisms of dis-
ease, with personalized regimens targeting differing pathologic fea-
tures of T1D based on clinical presentation [11,12].
In parallel, emerging preclinical and clinical data from persons at risk
of, or with, early T1D have emphasized an expanding role for activation
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through neoantigen formation or act independently to accelerate
autoimmune-mediated beta cell death [10]. These data suggest that, in
combination with immunomodulatory interventions, therapeutics
specifically targeting the beta cell may improve disease remission
efforts. However, interpreting treatment effects of interventions tar-
geting beta cell health in T1D requires a clear understanding of the
natural history and contributions of beta cell dysfunction to T1D
development. Recent evidence supporting the idea that beta cells are
stressed and dysfunctional in individuals with established T1D has
been comprehensively reviewed [13]. Here, we describe what is
known about changes in beta cell function before clinical T1D devel-
opment in humans at increased risk for T1D, and data suggesting that
beta cell dysfunction may predate detectable autoimmunity in in-
dividuals at genetic risk for T1D.
2. BETA CELL FUNCTION RELATIVE TO T1D PROGRESSION
To date, most cohort studies have ascertained factors associated with
progression to T1D in individuals with higher risk human leukocyte
antigen (HLA) genotypes or islet autoantibodies (Abs) [14e23]. Pre-
dictors of progression to diabetes among these high-risk individuals
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Ab Antibody
AUC Area under the curve
DIPP Diabetes Prediction and Prevention Study
DPT-1 Diabetes Prevention Trial-Type 1
FDR First degree relative
FPIR First phase insulin response
GAD Glutamic acid decarboxylyase
HLA Human leukocyte antigen
HOMA-IR homeostasis model assessment of insulin resistance
IA2 islet tyrosine phosphatase 2
ICA Islet cell antibody
ICARUS Islet Cell Antibody Registers Users Study
IVGTT Intravenous glucose tolerance test
OGTT Oral glucose tolerance test
PI/C proinsulin/C-peptide
PTP Pathway to prevention
T1D type 1 diabetes
T2D type 2 diabetes
Reviewnumbers of positive islet autoAbs, and dysfunctional glucose stimu-
lated insulin secretion [14e16,20e22].
2.1. Early studies describing decreased first phase insulin
response before clinical T1D onset
Early metabolic testing studies in nondiabetic persons who eventually
developed clinical T1D (progressors) identified first phase insulin
response (FPIR) reductions prior to the development of dysglycemia.
The Joslin Diabetes Center described IV glucose tolerance testing
(IVGTT) of 9 individuals before T1D diagnosis (including first degree
relatives (FDRs) of individuals with T1D, as well as individuals who had
been incidentally found to have glucosuria) [24,25]. These analyses
demonstrated progressively reduced FPIR on serial intravenous
glucose tolerance tests (IVGTTs), with responses decreasing dramat-
ically in the year preceding overt T1D [24,25]. In all but one of these
individuals islet cell antibody (ICA) or activated T cell positivity predated
clinical diabetes onset [24]. Abnormal fasting or stimulated glucose
values were only present the year before T1D clinical diagnosis [24].
Follow-up IVGTT data from 35 ICAþ FDRs over w4 years confirmed
that decreases over time to below the 1st percentile were highly
predictive of impending diabetes [14].
Subsequent studies confirmed that reduced FPIR is associated with
Abþ status and diabetes progression. In a cross-sectional IVGTT
analysis of 66 ICAþ FDRs, 38% of children and 16% of adults showed
FPIRs <2 standard deviations below normal [26]. Among children
followed longitudinally for diabetes development, very severely
decreased FPIR was strongly associated with progression over the next
12 months [26]. Prospective analyses of additional nondiabetic FDRs in
the US and Australia have shown that, compared to FDRs with un-
detectable Abs, FDRs positive for ICA or insulin Abs exhibit reduced
FPIR on IVGTT [16,27e30]. However, these studies yielded conflicting
results regarding whether adding FPIR to other variables known to be
associated with progression to T1D in relatives with multiple Abs
improved T1D prediction or whether adjusting FPIR for insulin resis-
tance added benefit [16,27e30]. The Islet Cell Antibody Register Users
Study (ICARUS) combined data sets from >20 research groups to
explore interactions of Abs, age and FPIR on T1D risk in 456 verified
ICAþ FDRs, including 245 who underwent at least one IVGTT [15].
ICARUS confirmed that FPIR loss is highly predictive of short-term risk,S130 MOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This isbut that FPIR’s performance as a risk predictor is significantly modified
by Ab titers and age [15].
The British Diabetic Twin Study followed 27 monozygotic twins of T1D
probands for at least 18 years after diagnosis of the index twin [31].
Over this period, 12/27 twins progressed to T1D (progressors) [31].
Compared to twins that did not progress over this period (non-
progressors), progressors exhibited higher fasting insulins, but lower
FPIRs on initial IVGTTs (obtained a mean of 3 years before diagnosis)
[31]. The Childhood Diabetes in Finland Study followed siblings of
affected individuals from the time of proband diagnosis, performing
IVGTTs at 6e12 month intervals once the sibling developed ICA or
insulin Ab positivity [32]. Among 13 ICA and/or insulin Abþ siblings in
this cohort who progressed to T1D and had repeated pre-diagnosis
IVGTT data available, FPIR was reduced in progressors compared to
non-progressors at all time points [32]. Intraindividual values fluctu-
ated considerably, and no significant reduction from baseline values
was detected in tests performed more proximal to diagnosis, pointing
away from a linear progression of beta cell decline before diagnosis
[32]. Among these Abþ siblings, higher ICA titers, higher risk HLA
genotypes and HLA identical genotypes to probands were associated
with lower FPIR values [33]. These studies hinted that more chronic
beta cell dysfunction (before the period immediately preceding T1D
diagnosis) may be present in those destined to progress to diabetes.
2.2. Metabolic natural history data arising from prevention studies
Subsequently metabolic analyses performed as part of several large-
scale T1D prevention trials became available. These data permitted
more systematic prospective analysis of the natural history of meta-
bolic progression of T1D.
The Finnish Type 1 Diabetes Prediction and Prevention Study (DIPP)
followed children with high-risk HLA genotypes based on general
population newborn screening for development of ICA, insulin Ab,
glutamic acid decarboxylase Abs (GADA), or IA2 Abs [34]. Children who
had >1 islet Ab were monitored with serial IVGTTs. Most participated
in a randomized double-blinded trial of intranasal insulin, which had no
effect on diabetes development [34]. For the 218 children with
metabolic data, decreasing quartiles of FPIR were associated with
higher rates of progression [22]. Here, higher homeostasis model
assessment of insulin resistance (HOMA-IR) values were associated
with increased risk of progression for individuals with the lowest FPIR
[22].
The European Nicotinamide Diabetes Intervention Trial (ENDIT) treated
552 nondiabetic ICAþ FDRs aged 3e40 years with nicotinamide or
placebo [35]. All study participants had baseline IVGTTs and serial
OGTTs (with fasting and 120-minute timepoints) [36]. A FPIR <10th
percentile for age at study entry was associated with a hazard ratio of
2.94 (95% Confidence Interval 2.06e4.20) for clinical diabetes
development by the end of the w5 year follow-up period [36]. How-
ever, not everyone who progressed had low baseline FPIR; 36% of
individuals who eventually developed T1D had baseline FPIRs above
the 10th percentile for age [36]. Similar to the DIPP, study, higher
HOMA-IR was only independently associated with progression for in-
dividuals with very reduced FPIR [37].
The Belgian Diabetes Registry studied baseline metabolic status of 17
nondiabetic IA-2Aþ (16/17 multiple Abþ) FDRs with OGTTs and hy-
perglycemic clamp studies as part of an ultimately negative prevention
study testing the effects of low-dose subcutaneous insulin injections
[20,38]. Compared to nonprogressors (followed forw 94 months) first
and second phase C-peptide absolute values were reduced among
progressors (obtained 3e62 months before diagnosis) [20]. 5/5 FDRs
with low first phase release progressed to T1D (over 3e21 months)an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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but 2/7 FDRs with normal first phase and abnormal second phase
release also developed T1D after 34 and 63 months of follow-up,
suggesting that other secretory defects may be present further out
from T1D diagnosis [20]. Follow-up data from a larger group classified
81 Abþ FDRs based on outcomes over 3 years of follow-up [21].
Among the 14 progressors, fasting glucose and OGTT glucose area
under the curve (AUC) were increased while both OGTT and clamp-
derived (first and second phase) C-peptide measures were
decreased. Here, clamp-derived first-phase C-peptide more clearly
distinguished progressors from nonprogressors than the OGTT derived
parameters tested (fasting and 2 hr glucose, glucose AUC, C-peptide
AUC, and peak C-peptide) [20,21].
2.3. The Diabetes Prevention Trial-Type 1 (DPT-1)
The Diabetes Prevention Trial-Type 1 (DPT-1) study group conducted
two randomized control trials testing effects of oral and parenteral
insulin to prevent T1D. This study group’s publications are the source
of the most extensive available published pre-diagnosis metabolic
analyses.
In DPT-1 non-diabetic 1st and 2nd-degree relatives 3e45 years of age
were screened for ICA [39,40]. ICAþ relatives underwent risk as-
sessments including IVGTT and 2-hr OGTT. Individuals with low FPIR or
abnormal glucose tolerance were included in the parenteral insulin
trial; those with normal FPIR who tested positive for insulin Abs were
included in the oral insulin trial. Participants in both trials underwent
biyearly OGTTs that included q30 min glucose and C-peptide mea-
surements. The DPT-1 verified reduced FPIR as a risk factor for pro-
gression to T1D, and also yielded multiple publications of analyses of
the longitudinal OGTTs [41].
2.3.1. Changing OGTT C-peptide responses during DPT-1
monitoring
Longitudinal DPT-1 data analyses suggested that the peri-onset period
(defined as 6 months prior to diagnosis), was associated with a rapid
metabolic decompensation, including markedly increased fasting and
stimulated glucose values, decreases in C-peptide peak and AUC
values, and increases in fasting C-peptide [42,43]. Interestingly, lon-
gitudinal analysis of glucose and C-peptide OGTT values from 52
progressors over the earlier time period of 30 to 6 months prior to
diagnosis demonstrated other abnormalities [17]. Glucose measures
increased gradually during this period, without significant changes in
fasting, peak, or AUC C-peptide [17]. Further analyses suggested that
this was due at least partially to a timing shift in peak insulin secretion
[44]. Thirty-six progressors with >¼2 years of pre-diagnosis OGTT
data were then compared to 80 nonprogressors. The progressors’
30 min minus 0 min (30-0) early C-peptide secretion, which correlates
with the FPIR, was already decreased at 2 years before diagnosis and
continued to fall until 6 months prior to diagnosis. However, over this
same period, they also exhibited delays in the peak C-peptide and an
increase in the late C-peptide response [44]. Altogether, 40% of
progressors compared to 22% of nonprogressors exhibited a “late” C-
peptide response; however, these shifts resulted in similar total AUC or
peak C-peptide values [42,44]. Because of this phenomenon, during
this period of monitoring, the timing of the C-peptide peak was more
predictive of progression than its absolute value [44].
2.3.2. Dysglycemia in DPT-1
During DPT-1 dysglycemic OGTTs were common amongst both pro-
gressors and nonprogressors; for 136 progressors and 275 non-
progressors with at least 3 OGTTs, incident dysglycemic OGTTs occurred
in 95% of progressors and 55% of nonprogressors [45]. AlthoughMOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This is an open a
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it is important to note that progressors frequently oscillated between
dysglycemic and normal OGTTs [45]. Longitudinal analysis of these
oscillating OGTTs showed that the disease was not truly remitting since
glucose levels, although sometimes technically in the normal range,
exhibited progressive increases over time [18]. Intraindividual OGTT C-
peptide values and early C-peptide responses showed that dysglycemic
OGTTs or OGTTs transiently in the diabetic range were actually asso-
ciated with higher C-peptide values [18]. These results suggest that
transient dysglycemic or diabetic range OGTTs are associated with
changes in insulin sensitivity in progressors.
2.3.3. Reduced beta cell glucose sensitivity is present in
progressors
OGTT glucose and C-peptide data from the 328 relatives enrolled in the
DPT-1 placebo arms (followed for a median of 2.7 years, 3.2 years for
nonprogressors alone) were placed into mathematical models to
calculate insulin sensitivity and beta cell glucose sensitivity (the slope of
the curve plotting doseeresponse of insulin secretion relative to plasma
glucose on OGTT) [46]. At baseline, despite similar fasting and stimu-
lated insulin levels as nonprogressors, progressors exhibited reduced
beta cell glucose sensitivity [46]. In fact, along with young age,
decreased baseline glucose sensitivity was the strongest independent
predictor of progression to clinical diabetes [46]. Consistent with other
reports of rapid metabolic decompensation in the months immediately
prior to diagnosis [17,42], for the 208 individuals who had>¼ 4 OGTTs
performed, 70% of progressors exhibited a biphasic pattern to
increasing 2-hour glucose values, with rapid increases only occurring
0.78 years before diagnosis [46]. This worsening dysglycemia was
accompanied by a rapid decrease in insulin sensitivity. By contrast,
dramatic reductions in beta cell glucose sensitivity from baseline began
to occur 1.45 years before diagnosis, suggesting that this dysfunction
predates hyperglycemia progression [46]. These findings suggested that
measures of beta cell function that are interpreted concurrently with
changes in glucose and insulin/C-peptide are more physiologically
relevant than measures of glycemia or absolute insulin measures alone.
2.3.4. T1D TrialNet pathway to prevention
Given the challenges with feasibility of larger-scale T1D prevention
studies, the National Institutes of Health, in cooperation with the
American Diabetes Association, and Juvenile Diabetes Research Foun-
dation developed Type 1 Diabetes TrialNet, an international network of
clinical sites performing T1D intervention and prevention trials (www.
trialnet.org) [47]. TrialNet also conducts the Pathway to Prevention
(PTP) study, designed to improve understanding of the natural history of
developing T1D. The design of PTP was based on DPT-1, but in-
corporates screening of first, second, and third degree relatives of in-
dividuals with T1D with biochemical islet Abs instead of ICA [47]. Risk
assessments to date have involved 2-hour OGTTs performed every 6e
12 months [47].
Based on lessons learned from DPT-1 suggesting that better risk
assessments can be achieved using measures incorporating timing of
C-peptide peak, as well as glucose and insulin levels in concert,
metabolic risk scores and indices have been generated and validated
using DPT-1 and TrialNet PTP data. These scores/indices can more
accurately identify metabolic dysfunction and better predict T1D pro-
gression than insulin/C-peptide or glucose measures alone [48e53].
Work from TrialNet has also linked other markers to changes in insulin
secretory kinetics in progressors, including circulating cell-free
unmethylated insulin DNA (marker of beta cell death) and altered
shapes of the OGTT glucose response curve [54,55].ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S131
Table 1 e Studies comparing beta cell function in relatives of probands with T1D to controls without a T1D family history.
Study/Year Country Methods Results
Rosenbloom et al.
Metabolism 1973
[67]
US OGTTs in 180 siblings of children with diabetes compared to 54 “normal”
controls.
58/180 siblings had glucose values that were abnormal by “liberal criteria”
(fasting blood glucose >115 mg/dL, 1hr glucose>150, and 2hr glucose
>130.) Repeat OGTT testing revealed that half of these children had
delayed peak insulin secretion and half were hyperinsulinemic.
Johansen et al.
NEJM 1975 [71]
US OGTT, cortisol primed OGTT, and IV tolbutamide testing in 11 monozygotic
twins matched by age, sex, and weight to nonrelative controls.
Insulin tended to be increased on OGTT, but only significant on cortisol
primed OGTT of twins, while glucose was normal. Growth hormone release
increased in twins.
Ginsberg-Fellner
et al. Diabetes
1982 [74]
US OGTT in 83 siblings, 67 parents, and 48 nonrelative pediatric controls. In siblings, HLA identical status (n ¼ 25) but not ICAþ status were
associated with higher glucose excursions and lower insulin secretion.
ICAþ parents (n ¼ 13) showed higher glucose and higher insulin levels
than to ICA- parents.
Hollander et al.
Diabetes 1982
[73]
US IV glucose and arginine testing on 14 siblings of T1D probands and
nonrelative controls matched for age, sex, weight, and height
Acute insulin response was increased in HLA identical siblings only.
Srikanta et al. Ann
Intern Med 1983,
Diabetes 1984
[24,25]
US IV GTT in 15 ICA- monozygotic twins of T1D probands Although repeated insulin measurements were variable among twins,
compared to a historical control population, no twins had insulin
levels< 1st percentile. Only 1/15 twins exhibited progressive reductions in
stimulated insulin levels.
Schober et al. Arch
Dis Child 1983
[72]
Austria OGTT in 66 siblings of T1D probands stratified by HLA similarity to proband
and compared to 33 unrelated controls.
HLA identical siblings (n ¼ 19) mostly showed significantly higher insulin
response to glucose (except for 3/19 with very low insulin responses)
Johnston et al.
Diabetes 1987
[75]
US IVGTT and arginine stimulation in 12 ICA- adult siblings (>16 years since
diagnosis of proband) compared to age, sex, weight matched controls
Insulin sensitivity was reduced in siblings. Absolute maximum acute
arginine response was reduced in siblings, but all phases of insulin
secretion were reduced after adjustment for insulin sensitivity.
Heaton et al. Br Med
J 1987 [79]
UK OGTTS and IVGTTs performed on 10 “low-risk” ICAþ identical twins of
probands with longstanding T1D (developed 11e23 years prior), but no
personal history of dysglycemia. Compared to age, sex, and BMI matched
nonrelative controls.
Compared to controls, low-risk twins had 2-fold increase in fasting
proinsulin despite similar C-peptide, glucose, and insulin levels. Twins also
showed increased insulin responses to IV glucose and OGTT despite similar
glucose excursions.
Heaton et al.
Diabetologia
1988 [80]
UK IVGTT and OGTT performed on 11 identical twins with recently diagnosed
twin with T1D (<2 years). 5/11 ICAþ, 6/11 were ICA-. 2/6 of ICA- group
were insulin Abþ. Compared to controls.
Compared to controls, fasting proinsulin increased w2 fold among ICA-
and ICAþ twins, despite similar glucose, insulin, and C-peptide. Stimulated
glucose excursions were increased in ICAþ twins.
Vialettes et al.
Diabetologia
1988 [69]
France IVGTT in 150 first degree relatives (16/150 were ICA Abþ) compared to 67
controls as well as 31 first degree relatives of individuals with T2D.
12% of T1D relatives had FPIR <5th percentile of controls. No effect of
ICAþ on FPIR was detected. Rates of decreased FPIR were similar in T2D
relatives (13%).
Hartling et al.
Diabetes 1989
[76]
Sweden Fasting proinsulin and insulin were measured in 99 siblings of T1D
probands and 41 nonrelative controls matched for age and sex. All siblings
were insulin Ab- and only 2/99 were ICAþ. Most siblings had been
followed for >6 years without T1D development.
Fasting proinsulin was >2 fold increased among siblings, although insulin
was slightly reduced. Fasting proinsulin/insulin ratios were significantly
increased. Effect was independent of high-risk HLA status.
Lindgren et al.
Diabetic Medicine
1991 [81]
Sweden Performed IV glucose infusion tests and somatostatin-insulin-glucose
infusions on 93 ICA- and insulin Ab- siblings of T1D probands (same cohort
as [76]) compared to 41 nonrelative controls matched for age and sex.
After adjustment for insulin sensitivity, siblings showed reduced total
insulin response and increased proinsulin release in response to IV glucose
infusion.
Spinas et al.
Diabetes Care
1992 [82]
Denmark Fasting glucose, insulin, and proinsulin measured in 85 first degree
relatives (siblings, parents, and children; primarily adults) compared to 90
age and weight matched non-relative controls.12/85 relatives were
ICAþ and 11/85 were insulin Abþ.
Similar glucose and insulin among relatives and controls but fasting
proinsulin was>4 fold increased in relatives. ICA positivity associated with
higher proinsulin values. No effect of HLA similarity to proband or insulin
antibody positivity was observed.
Carel et al. JCI 1993
[70]
France IVGTT performed on 98 ICA- and Insulin Ab- pediatric siblings of T1D
probands compared to 167 nonrelative controls.
Siblings had a 25% reduction in FPIR. Subgroup analysis revealed this
effect was only present in siblings >8 years of age.
Hawa et al. Diabetes
Care 2005 [31]
UK Follow-up to British Twin Study- At least 2 IVGTTs performed on 27
monozygotic twins of T1D probands followed prospectively for >¼ 18
years and compared to nonrelative controls with similar age and body
habitus.
15 twins who did not develop T1D (mean 24.1 years of age at first test)
remained Ab- and showed no differences in FPIR, HOMA-IR, fasting insulin,
fasting glucose, or glucose clearance compared to nonrelative controls.
Truyen et al.
Diabetologia
2005 [62]
Belgium Random proinsulin/C-peptide ratios obtained in in 561 Abþ FDRs and 561
Ab- FDRS.
Manuscript notes per personal communication that values for Ab- relatives
and nonprogressor Abþ relatives were similar to a group of 22 nonrelative
controls.
Ferrannini et al.
Diabetes Care
2010 [46]
US Modeling of insulin sensitivity and beta cell glucose sensitivity using OGTTs
in 213 ICAþ nonprogressors (followed median of 3.2 years) in DPT-1.
Discussion notes that at baseline, nonprogressors had reduced beta cell
glucose sensitivity and insulin sensitivity compared to historical controls.
Sosenko et al.
Diabetes Care
2012 [42]
US Classification of OGTT data from ICAþ DPT-1 nonprogressors into “early”
or “late” responders based on timing of OGTT C-peptide peak from
historical data from nonrelative controls.
Nonprogressors noted to have significantly higher prevalence of late
responders (22%) compared to controls (6%).
Vandemeuleboucke
et al. Diabetologia
2010 [20] and
Balti et al. JCEM
2014 [21]
Belgium 1. Hyperglycemic clamp and OGTT in 10 IA2þ (mostly multiple Abþ FDRs)
that did not progress to T1D (7.8 year median follow-up) and 21 nonrelative
controls.
2. Hyperglycemic clamps and OGTTs in 67 Abþ nonprogressors (over 3
years of follow-up), Ab- FDRs (n ¼ 10, n ¼ 20, for first phase and second
phase measurements) and transient Abþ FDRs (n ¼ 7e9) vs. controls.
No differences in glucose or C-peptide measures among
Abþ nonprogressors, Ab- FDRs, transiently Abþ FDRs, and nonrelative
controls.
Siewko et al.
Endokrynol Pol
2014 [65]
Poland IVGTT performed in 90 adult FDRs of T1D index cases (only 30% were
Abþ) and compared to 60 nonrelative controls.
FPIR was significantly reduced among relatives. Ab positivity was not
significantly different between quartiles of first phase insulin secretion.
Campbell
eThompson
et al. Diabetes
Care 2019 [83]
US Pancreatic MRI performed to calculate pancreas volume in 49 nonrelative
controls, 61 Ab- FDRs, 67 Abþ FDRs, and 52 participants with recent-
onset T1D.
Pancreas volume was reduced in Ab- FDRs and Abþ FDRs compared to
controls, although not as severely reduced as in participants with recent-
onset T1D.
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2.4. Elevations in circulating proinsulin/C-peptide (PI/C), a marker
of beta cell stress and dysfunction, are associated with T1D
progression
In addition to traditional metabolic measures of beta cell function,
circulating biomarkers that reflect events occurring within the beta cell
on a molecular level can provide additional insight into beta cell
dysfunction [56]. For example, beta cells undergoing intracellular
stress accumulate inadequately processed, immature proinsulin mol-
ecules [57]. Along these lines, compared to nondiabetic control donors,
islets from Abþ individuals contain normal insulinþ beta cell mass,
but increased proinsulinþ area, while islets from individuals recently
diagnosed with T1D display reduced insulinþ beta cell mass, and
increased proinsulin/insulin positive area [58]. Because accumulating
proinsulin molecules are also released into the circulation, elevations in
circulating proinsulin levels relative to insulin or C-peptide can be used
as a measure of beta cell stress and dysfunction [57,59,60].
Several groups have linked T1D progression to elevations in the ratios of
circulating proinsulin to mature insulin or to C-peptide. In the Childhood
Diabetes in Finland study, 11 ICAþ and/or insulin Abþ siblings with
severely reduced FPIR on IVGTT were compared to age and sex-matched
siblings with normal FPIR [61]. Fasting proinsulin/C-peptide (PI/C) values
were 2e3 fold higher in the group with low FPIR and were inversely
related to first-phase and stimulated insulin responses [61]. Of 11 sib-
lings with high PI/C and low FPIR, 9/11 progressed to T1D over the next
1e28 months, while none of the siblings with lower PI/C and higher FPIR
progressed over this period [61].
Increases in PI/C levels have also been linked to progression among
Abþ relatives of T1D probands. Within the Belgian Diabetes Registry,
baseline random PI/C ratios were increased among 338 Abþ FDRs
compared to 561 age and sex matched Ab- FDRs [62]. Longitudinal
samples from 32 individuals who progressed to T1D suggested that PI/
C values were inversely associated with length of time until diagnosis.
PI/C ratios above the 66th percentile were associated with a risk of
progression of 50% for multiple Abþ relatives and 68% for islet
tyrosine phosphatase (IA2)þ relatives vs. a risk of 13% for those with
lower ratios [62]. Further analyses suggested that fasting PI/C ratios
may perform even better for T1D risk prediction when adjusted for
insulin sensitivity [63]. Among Abþ relatives in the TrialNet PTP study
in serum samples obtainedw12 months before T1D diagnosis higher
PI/C ratios were associated with increased odds of T1D progression,
even after adjustment for age, sex, and BMI-Z scores [64]. Interest-
ingly, direct comparisons of progressors to non-progressors divided
into young pediatric, adolescent, and adult age groups suggested that
in the PTP cohort, significant differences between progressors and
nonprogressors were only present in the youngest pediatric group
(<¼10 years of age) [64].
3. BETA CELL DYSFUNCTION IS PRESENT LONG BEFORE T1D
ONSET
These cohorts have provided data to support the critical understanding
that, although rapid beta cell losses occur in the years and months
immediately preceding T1D onset, abnormalities in insulin secretion
are present even years earlier [17e19,23,25]. As an example, 22/52
(42%) of Finnish children followed as part of the DIPP Study with
increased-risk HLA genotypes who had recently converted to
ICAþ status showed subnormal FPIR by IVGTT [65]. At the time of
publication, half of the children with low FPIR had not progressed to
T1D, despitew2.9 years (2e4.4 years) of follow up, suggesting that
altered insulin secretion may be present before the period immediately
preceding clinical diagnosis [65]. Follow up data from the DIPP cohortMOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This is an open a
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seroconversion 1.6 and 4.6 years, respectively, and age of T1D
diagnosis in progressors of 6.6 years) [23]. Here, despite similar
glucose values to nonprogressors, progressors had significantly lower
FPIR starting around 4e6 years prior to T1D diagnosis [23]. In
Abþ relatives monitored through the TrialNet PTP for at least 5 years
before diabetes progression (mean age of diagnosis of 21.6 years),
compared to Ab- relatives, abnormalities in fasting and stimulated C-
peptide levels were already present at the initial OGTT, a mean of
6.6  1.3 years before diagnosis [66].
These findings not only suggest that chronic abnormalities in beta cell
function in Abþ individuals with genetic risk who progress to T1D, but
also raise the possibility that inherited abnormalities in beta cell
function may be present and contributing to ultimate T1D risk. Because
most cohorts studied only performed metabolic analyses after the
development of Ab positivity, these works are unable to make this
distinction. However, a significant body of work exists that suggests
that family members of individuals with T1D are at increased risk for
altered beta cell function compared to nonrelative controls.
4. ARE ABNORMALITIES IN BETA CELL FUNCTION PRESENT IN
FAMILY MEMBERS OF INDIVIDUALS WITH T1D COMPARED TO
NONRELATIVE CONTROLS?
Because much of the newer available data have focused on the use of
large cohorts to better understand factors associated to progression of
T1D to clinical disease, these works often compare features of “pro-
gressors” to “nonprogressors”. However this approach may obscure
abnormalities that are present in at-risk individuals who may not
progress to disease, but exhibit abnormal beta cell function compared
to true unrelated “controls”. Although such abnormalities may not
exclusively define individuals progressing to clinical disease, they
could still provide insights into mechanistic contributors to T1D
development. Along these lines, a significant body of cross-sectional
data examining family members of individuals with T1D compared to
non-relative controls suggests that b cell abnormalities may be present
in relatives (Table 1) [25,67e70]. These works describe abnormal
insulin release, as well as dysglycemic responses to OGTTs [67e70].
4.1. Early work suggests increased insulin secretion in relatives
Several papers published in the 1970s alluded to this phenomenon.
Interestingly, initial descriptions often described increased insulin
stimulatory responses in relatives of individuals with T1D. In an
analysis of 180 siblings of children with diabetes, 1/3 had increased
glucose values on a 2hr OGTT based on “liberal criteria” (fasting
glucose > 115 mg/dL, 1hr > 150 mg/dL, and 2 hr > 130 mg/dL)
[67]. 55 of these children completed a repeat 4 hr-OGTT; the OGTT
was normal in 26 (47%). Compared to nonrelative controls, both
groups with normal and abnormal glycemia on repeat OGTTs exhibited
differences in plasma insulin in response to glucose. Siblings with
abnormal repeat OGTTs exhibited a delayed peak in insulin rise, while
those with normoglycemic OGTTs exhibited pronounced hyper-
insulinemia in response to glucose [67]. Along these lines, analysis of
11 monozygotic twins showed normal glucose but increased insulin
responses to cortisol-primed OGTTs [71]. OGTT analyses of 66 siblings
stratified by HLA similarity to probands identified an exaggerated in-
sulin response only in siblings who were HLA-identical to probands
[72]. Similarly, IVGTT and arginine stimulation analysis of 14 siblings
with known HLA haplotypes suggested that, compared to controls,
acute insulin response was exagerated in the 9 individuals who shared
HLA haplotypes with affected siblings [73].ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S133
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important confounders
Subsequent to initial work, describing increased insulin excursions in
T1D relatives, other groups detected reduced insulin responses in
cross sectional analyses of relatives compared to controls. Compared
to matched nonrelative controls, IVGTT analysis of 150 FDRs (mean
age of 15.8 years, 16/150 ICAþ) identified severely reduced first
phase insulin responses in 12 participants [69]. This rate was not
impacted by ICA positivity and was similar to a 13% rate of reduced
FPIR in FDRs of individuals with type 2 diabetes (T2D) (13%) [69].
IVGTT of 98 ICA-, insulin Ab- pediatric siblings of individuals with T1D
showed a 25% reduction in insulin response compared to pediatric
controls [70]. This reduction was predominantly present in siblings
who were >8 years of age [70]. IVGTTs performed on a group of 90
adult FDRs (only 31% biochemical Abþ) revealed normal glucose
tolerance, with higher fasting insulin values but reduced FPIR
compared to controls [65]. Analysis of insulin response by quartiles did
not reveal any differences in prevalence of Ab positivity among quar-
tiles [65]. OGTT analysis of siblings and parents of individuals with T1D
suggested that differences in insulin response may be related to the
nature of the relationship to the proband with T1D [74]. Here, for
siblings (n ¼ 119), identical HLA status was associated with higher
(although not frankly abnormal) glucose excursions and lower insulin
responses, with no effect of ICA positivity on OGTT measures. By
contrast, in parents (n ¼ 128), ICA positivity was associated with
increased glucose and increased insulin release on OGTT, with no
effect of HLA status [74].
The differences between studies in observed increases vs. de-
creases in insulin secretion could be related to several factors,
including varying metabolic testing techniques, genetic and de-
mographic study group differences, control group matching, and
importantly, differences in insulin sensitivity. IV glucose and argi-
nine stimulation of 12 young adult HLA identical siblings (consid-
ered low risk based on >¼ 16 years having elapsed since
diagnosis of T1D in the sibling) compared to matched controls
suggested that siblings exhibited decreased insulin sensitivity [75].
Accordingly, all phases of insulin release were reduced only after
adjustment for insulin sensitivity [75].
An analysis of 99 normoglycemic siblings of individuals with T1D from
the Swedish Karolinska Institute examined secretory function using IV
glucose infusions adjusted for insulin sensitivity (as measured with
somatostatin-insulin-glucose infusions) [76]. Of these siblings, 97/99
were ICA- and insulin Ab- [76]. After adjustment for insulin sensitivity,
insulin responses were significantly reduced among siblings compared
to age-matched controls. Interestingly, when ICA- siblings were
grouped with HLA-similar probands, although considerable variability
existed, there were no differences between HLA groups in insulin
responses to glucose infusions after insulin sensitivity adjustments
[77]. Rather, age was the predominant factor linked to differences in
insulin response [77]. Cross sectional OGTT analysis of a large number
of nondiabetic FDRs (aged 2e75 years) suggested that, similar to
reports in control populations, insulinogenic index increased with age
through adolescence and decreased with age thereafter [78]. In this
group, multiple Abþ status (ICA, insulin Ab, GADA, and/or IA-2A) was
associated with reduced insulinogenic indexes but not with changes in
insulin sensitivity [78]. Reports from DPT-1 have also noted that,
despite similar insulin sensitivity, Abþ relatives that did not progress to
T1D had reduced baseline beta cell glucose sensitivity (a measure that
accounts for both C-peptide and glucose levels) compared to historical
controls [46].S134 MOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This is4.1.2. Studies suggesting similar insulin secretion between
relatives and non-relative controls
Several studies have also pointed away from altered insulin secretion
or insulin sensitivity in relatives of individuals with T1D at lower risk for
diabetes progression. Subsequent work from the Joslin twin registry
noted that among 15 nondiabetic ICA- twins, although substantial
variability in insulin responses to IVGTTs was present, only one twin
exhibited progressive decrease in insulin release over 17 years of
follow-up, and none had insulin levels < the 1st percentile compared
to the group’s control population [24,25]. Comparison of IVGTTs from
15 Ab- nondiabetic monozygotic twins of individuals with T1D in the
British Diabetic Twin Study to nonrelative controls with similar age and
BMIs showed no differences in FPIR, HOMA-IR, fasting insulin, fasting
glucose, or glucose clearance [31]. Hyperglycemic clamp and OGTT
studies from the Belgian Diabetes Registry did not identify any dif-
ferences in glucose or C-peptide measures among 10 multiple
Abþ FDRs that did not progress to T1D over a 94 month period
compared to a group of nonrelative controls or amongst a group of Ab-
FDRs or transiently Abþ FDRs [20,21]
4.2. Other markers of beta cell dysfunction are abnormal in some
relatives of individuals with T1D
Several older studies have detected PI/C ratio elevations in relatives of
T1D probands [61,79e82]. When compared to age, sex, and BMI
matched nonrelative controls, 10 ICAþ nondiabetic identical twins of
individuals with longstanding T1D judged to be low risk for progression
(based on long durations ranging from 11 to 23 years since the
diagnosis of the twin proband) exhibited normal glycemic excursions
on OGTT, but abnormally increased C-peptide responses, as well as
abnormally increased fasting and stimulated serum proinsulin levels
[79]. Interestingly, 6 ICA- identical twins (2/6 positive for insulin au-
toantibodies, mean of 17 months since diagnosis) exhibited normal
glucose and insulin/C-peptide responses to OGTT but also displayed
elevated fasting proinsulin levels [80].
Another analysis of fasting proinsulin levels performed in a cross-
section of 85 FDRs suggested that, compared to age and weight-
matched non-relative controls, although fasting glucose and insulin
values were similar, fasting proinsulin levels were increased in par-
ents, siblings, and children of individuals with T1D [82]. The 12
ICAþ individuals analyzed as part of this study had higher fasting
proinsulin than ICA- relatives, but ICA- relatives also had elevated
values compared to controls. No effect of insulin Ab positivity or HLA
similarity to proband was detected [82]. The Karolinska Institute
analysis of 99 predominately ICA- and Insulin Ab- normoglycemic
siblings of T1D probands described above also identified increases in
fasting proinsulin/insulin ratios compared to nonrelative age-matched
controls [76]. HLA status had no effect on ratios [76]. Similar to fasting
values, stimulated proinsulin levels in response to glucose infusions
were increased in siblings, even after adjustment for insulin sensitivity
[81]. By contrast, similar to reports of clamp derived measures, a
Belgian Diabetes Registry report noted that random ratios of
Abþ nonprogressor FDRs and Ab- FDRs were similar to values from a
group of 22 nonrelative controls [62].
Finally, although not an analysis of beta cell function per se, a recent
cross-sectional study described reduced pancreas volumes on MRI in
Ab- FDRs compared to nonrelative controls [83]. Volumes were pro-
gressively further decreased in Abþ nondiabetic relatives and in in-
dividuals with recent onset T1D [83]. These findings raise the
possibility that inherited differences in whole pancreas, including islet,
function and/or mass may exist in families with T1D.an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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5. IMPLICATIONS OF DATA SUGGESTING BETA CELL
DYSFUNCTION EXISTS IN SOME RELATIVES WHO DO NOT
PROGRESS TO T1D
There are multiple possible interpretations of these data suggesting
longstanding beta cell dysfunction in progressors, as well as in Abþ
nonprogressors and Ab- relatives. The observed abnormalities in Ab-
FDRs or Abþ nonprogressors could reflect early signs of an ultimate
progression to clinical diabetes over the course of the individual’s
lifetime that has not become manifest by the end of the period of
study observation. Because longitudinal metabolic analyses are not
typically performed until after the development of Abs, it is impos-
sible to know the true “baseline” metabolic status of these in-
dividuals. In Ab- relatives, abnormal beta cell function could reflect
very early ongoing autoimmunity undetected by current Ab mea-
surements or sequelae of a prior autoimmune attack that subse-
quently resolved. Alternatively, some individuals at risk for T1D may
also inherit abnormalities in beta cell function. The presence of this
beta cell dysfunction in “nonprogressors” and Ab- FDRs could reflect
that these beta cell abnormalities do not increase risk, since most of
these relatives will not ultimately get diabetes. Alternatively, beta cell
dysfunction may be associated with increased risk, but not sufficient
for T1D development. In this way, T1D may develop due to “multiple
hits”, including inherited predisposition to autoimmunity, environ-
mental exposures that activate autoimmunity, and defects in beta
cell mass, function, turnover, or survival.
Although differences in HLA genotype account for the largest known
contributor to T1D risk, candidate gene and genome-wide association
studies have also identified other genetic variants that have smaller
effects [84]. Although these variants are classically linked to differ-
ences in immune function and tolerance, at least half are also
expressed in islets [85]. Many of these genes regulate proinflammatory
and apoptotic pathways in the beta cell, and undergo alternative
splicing in the islet, which is substantially impacted by treatment with
inflammatory cytokines [85e87]. Inherited differences in beta cell
gene expression may interact with the immune system to trigger or
exacerbate the autoimmune response. As another example, among
subgroups of individuals with T1D, polymorphisms in the transcription
factor 7-like 2 (TCFL2) gene, which are associated with beta cell
dysfunction in Type 2 diabetes, have been linked to increased risk of
progression despite a milder immunologic phenotype than that of other
progressors [88,89]. This phenotypic difference may reflect to a lower
threshold for progression due to inherited beta cell dysfunction.
The body of work comparing nondiabetic relatives of individuals with
T1D to nonrelative controls, while intriguing, has some caveats which
make interpretation of the work as a whole challenging. Because older
studies were performed before newer pancreatic autoAb assays
became available, characterization of islet autoimmunity was more
limited, and thus, likely underestimated. Nonetheless, beta cell
dysfunction was identified at a higher prevalence than would be ex-
pected for Abþ positive status in relatives [90]. Older proinsulin and
insulin assays often exhibited significant cross-reactivity, complicating
interpretation of circulating proinsulin and insulin values. Additionally,
these data were often obtained only cross-sectionally, rather than
longitudinally. Longitudinal analyses with multiple time-points would
be preferable to exclude individuals who went on to develop diabetes,
especially given the now appreciated relapsing-partially remitting
nature of T1D onset [91].
Another important limitation in interpretation of this body of work is
differences in study designs. Studies have utilized multiple different
analyses for beta cell response, which could have led to differingMOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This is an open a
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glucose absorption during OGTTs. Definitions of abnormal results
differed, even when using the same testing modalities. Studies also
enrolled different age groups of participants. Given the well-recognized
effects of age on beta cell function, insulin sensitivity and diabetes risk,
differences between beta cell function in study populations could be
related to age differences among groups. Appropriately-matched
controls for age and body habitus are not always documented and
could also be a contributing factor to differing study results. Lastly,
given the heterogenous nature of T1D [91], inherited beta cell
dysfunction may only be present in subpopulations of at-risk in-
dividuals, and so may not be reflected in small sample sizes or
comparison of summary statistics between larger groups.
6. CONCLUSIONS
Notwithstanding these limitations, these important data suggest that
contributions of beta cell dysfunction to the pathology of developing
T1D need to be further explored as we work toward prevention and
cure of this disease. Continued identification of molecular signaling
pathways leading to beta cell stress, dysfunction, and death
associated with genetic variants linked to increased T1D risk will be
key to providing mechanistic insights into these relationships.
Robust analyses of beta cell function and stress in Ab- relatives
tested with newer Ab assays, as well as individuals harboring
high risk polymorphisms potentially contributing to beta cell
dysfunction or T2D susceptibility genes will be important to better
understand in vivo contributions of beta cell dysfunction to T1D
development. Identification of the optimal tools or biomarkers to
identify beta cell dysfunction in this context will maximize appli-
cability of studies moving forward. Additionally, identification of
markers differentiating reversible (ie treatable) vs irreversible beta
cell dysfunction will be needed to determine which individuals may
benefit from therapies targeting beta cell health. Lastly, studies
evaluating impacts of beta-cell targeted therapies will be crucial to
determine if these types of reagents may improve outcomes of
immunomodulatory therapies in individuals exhibiting indicators of
potentially reversible beta cell stress/dysfunction. Ultimately, these
efforts may lead to more of a precision-medicine type approach to
diabetes prevention and treatment, in which agents targeting beta
cell health are combined with immunomodulatory therapies to
improve efficacy in groups displaying high levels of reversible beta
cell dysfunction.
ACKNOWLEDGEMENTS
None.
CONFLICTS OF INTEREST
The authors have no competing interests to declare.
FUNDING
This manuscript was supported by funding from NIDDK K08DK103983 to E.K.S., R03
DK117253 to EKS, JDRF 2-SRA-2017-498-M-B to E.K.S.; U01DK107014 to L.A.D.
This article is part of a supplement entitled ‘Biomarkers of Beta-Cell Health and
Dysfunction: Towards Personalised Diabetes Care. Proceedings of the 20th Servier-
IGIS Symposium’. The Symposium and the publication of the Supplement have been
made possible by an unrestricted educational grant from Institut la Conférence
Hippocrate e Servier Group.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S135
ReviewREFERENCES
[1] Narayan, K.M., Boyle, J.P., Thompson, T.J., Sorensen, S.W., Williamson, D.F.,
2003. Lifetime risk for diabetes mellitus in the United States. Journal of the
American Medical Association 290(14):1884e1890.
[2] Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999.
Diabetic Medicine 23(8), 2006:857e866.
[3] Tao, B., Pietropaolo, M., Atkinson, M., Schatz, D., Taylor, D., 2010. Estimating
the cost of type 1 diabetes in the U.S.: a propensity score matching method.
Public Library of Science one 5(7):e11501.
[4] Dabelea, D., Mayer-Davis, E.J., Saydah, S., Imperatore, G., Linder, B.,
Divers, J., et al., 2014. Prevalence of type 1 and type 2 diabetes among
children and adolescents from 2001 to 2009. Journal of the American Medical
Association 311(17):1778e1786.
[5] Foster, N.C., Beck, R.W., Miller, K.M., Clements, M.A., Rickels, M.R.,
DiMeglio, L.A., et al., 2019. State of type 1 diabetes management and out-
comes from the T1D Exchange in 2016-2018. Diabetes Technology & Ther-
apeutics 21(2):66e72.
[6] Herold, K.C., Hagopian, W., Auger, J.A., Poumian-Ruiz, E., Taylor, L.,
Donaldson, D., et al., 2002. Anti-CD3 monoclonal antibody in new-onset type 1
diabetes mellitus. New England Journal of Medicine 346(22):1692e1698.
[7] Herold, K.C., Gitelman, S., Greenbaum, C., Puck, J., Hagopian, W., Gottlieb, P.,
et al., 2009. Treatment of patients with new onset Type 1 diabetes with a
single course of anti-CD3 mAb Teplizumab preserves insulin production for up
to 5 years. Clinical Immunology 132(2):166e173.
[8] Orban, T., Bundy, B., Becker, D.J., DiMeglio, L.A., Gitelman, S.E., Goland, R.,
et al., 2011. Co-stimulation modulation with abatacept in patients with recent-
onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Lancet 378(9789):412e419.
[9] Pescovitz, M.D., Greenbaum, C.J., Krause-Steinrauf, H., Becker, D.J.,
Gitelman, S.E., Goland, R., et al., 2009. Rituximab, B-lymphocyte depletion,
and preservation of beta-cell function. New England Journal of Medicine
361(22):2143e2152.
[10] Atkinson, M.A., Bluestone, J.A., Eisenbarth, G.S., Hebrok, M., Herold, K.C.,
Accili, D., et al., 2011. How does type 1 diabetes develop?: the notion of
homicide or beta-cell suicide revisited. Diabetes 60(5):1370e1379.
[11] Skyler, J.S., 2015. Prevention and reversal of type 1 diabetesepast challenges
and future opportunities. Diabetes Care 38(6):997e1007.
[12] Greenbaum, C., Lord, S., VanBuecken, D., 2017. Emerging concepts on
disease-modifying therapies in type 1 diabetes. Current Diabetes Reports
17(11):119.
[13] Oram, R.A., Sims, E.K., Evans-Molina, C., 2019. Beta cells in type 1 diabetes:
mass and function; sleeping or dead? Diabetologia 62(4):567e577.
[14] Vardi, P., Crisa, L., Jackson, R., Herskowitz, R.D., Wolfsdorf, J., Einhorn, D.,
et al., 1991. Predictive value of intravenous glucose tolerance test insulin
secretion less than or greater than the first percentile in islet cell antibody
positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia
34(2):93e102.
[15] Bingley, P.J., 1996. Interactions of age, islet cell antibodies, insulin autoan-
tibodies, and first-phase insulin response in predicting risk of progression to
IDDM in ICAþ relatives: the ICARUS data set. Diabetes 45(12):1720e1728.
[16] Colman, P.G., McNair, P., Margetts, H., Schmidli, R., Werther, G., Alford, F.,
et al., 1998. The Melbourne pre-diabetes study: prediction of type 1 diabetes
mellitus using antibody and metabolic testing. Medical Journal of Australia
169(2):81e84.
[17] Sosenko, J.M., Palmer, J.P., Greenbaum, C.J., Mahon, J., Cowie, C.,
Krischer, J.P., et al., 2006. Patterns of metabolic progression to type 1 dia-
betes in the diabetes prevention trialetype 1. Diabetes Care 29(3):643e649.
[18] Sosenko, J.M., Skyler, J.S., Krischer, J.P., Greenbaum, C.J., Mahon, J.,
Rafkin, L.E., et al., 2010. Glucose excursions between states of glycemia withS136 MOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This isprogression to type 1 diabetes in the Diabetes Prevention TrialeType 1 (DPT-
1). Diabetes 59(10):2386e2389.
[19] Sosenko, J.M., Skyler, J.S., Beam, C.A., Krischer, J.P., Greenbaum, C.J.,
Mahon, J., et al., 2013. Acceleration of the loss of the first-phase insulin
response during the progression to type 1 diabetes in diabetes prevention trial-
type 1 participants. Diabetes 62(12):4179e4183.
[20] Vandemeulebroucke, E., Keymeulen, B., Decochez, K., Weets, I., De Block, C.,
Fery, F., et al., 2010. Hyperglycaemic clamp test for diabetes risk assessment
in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia
53(1):36e44.
[21] Balti, E.V., Vandemeulebroucke, E., Weets, I., Van De Velde, U., Van Dalem, A.,
Demeester, S., et al., 2014. Hyperglycemic clamp and oral glucose tolerance
test for 3-year prediction of clinical onset in persistently autoantibody-positive
offspring and siblings of type 1 diabetic patients. The Journal of Cinical
Endocrinology and Metabolism 100(2):551e560.
[22] Siljander, H.T., Hermann, R., Hekkala, A., Lähde, J., Tanner, L., Keskinen, P.,
et al., 2013. Insulin secretion and sensitivity in the prediction of type 1 dia-
betes in children with advanced b-cell autoimmunity. European Journal of
Endocrinology 169(4):479e485.
[23] Koskinen, M.K., Helminen, O., Matomäki, J., Aspholm, S., Mykkänen, J.,
Mäkinen, M., et al., 2016. Reduced b-cell function in early preclinical type 1
diabetes. European Journal of Endocrinology 174(3):251e259.
[24] Srikanta, S., Ganda, O.P., Jackson, R.A., Gleason, R.E., Kaldany, A.,
Garovoy, M.R., et al., 1983. Type I diabetes mellitus in monozygotic twins:
chronic progressive beta cell dysfunction. Annals of Internal Medicine 99(3):
320e326.
[25] Srikanta, S., Ganda, O.P., Gleason, R.E., Jackson, R.A., Soeldner, J.S.,
Eisenbarth, G.S., 1984. Pre-type I diabetes. Linear loss of beta cell response to
intravenous glucose. Diabetes 33(8):717e720.
[26] Chase, H.P., Voss, M.A., Butler-Simon, N., Hoops, S., O’Brien, D.,
Dobersen, M.J., 1987. Diagnosis of pre-type I diabetes. The Journal of Pe-
diatrics 111(6 Pt 1):807e812.
[27] Krischer, J.P., Schatz, D., Riley, W.J., Spillar, R.P., Silverstein, J.H.,
Schwartz, S., et al., 1993. Insulin and islet cell autoantibodies as time-
dependent covariates in the development of insulin-dependent diabetes: a
prospective study in relatives. The Journal of Cinical Endocrinology and
Metabolism 77(3):743e749.
[28] Verge, C.F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Jackson, R.A.,
et al., 1996. Prediction of type I diabetes in first-degree relatives using a
combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes
45(7):926e933.
[29] Greenbaum, C.J., Sears, K.L., Kahn, S.E., Palmer, J.P., 1999. Relationship of
beta-cell function and autoantibodies to progression and nonprogression of
subclinical type 1 diabetes: follow-up of the Seattle family study. Diabetes
48(1):170e175.
[30] Fourlanos, S., Narendran, P., Byrnes, G.B., Colman, P.G., Harrison, L.C., 2004.
Insulin resistance is a risk factor for progression to type 1 diabetes. Dia-
betologia 47(10):1661e1667.
[31] Hawa, M.I., Bonfanti, R., Valeri, C., Delli Castelli, M., Beyan, H., Leslie, R.D.,
2005. No evidence for genetically determined alteration in insulin secretion or
sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes
Care 28(6):1415e1418.
[32] Knip, M., Vahasalo, P., Karjalainen, J., Lounamaa, R., Akerblom, H.K., 1994.
Natural history of preclinical IDDM in high risk siblings. Childhood Diabetes in
Finland study group. Diabetologia 37(4):388e393.
[33] Veijola, R., Vahasalo, P., Tuomilehto-Wolf, E., Reijonen, H., Kulmala, P.,
Ilonen, J., et al., 1995. Human leukocyte antigen identity and DQ risk alleles in
autoantibody-positive siblings of children with IDDM are associated with
reduced early insulin response. Childhood diabetes in Finland (DiMe) study
group. Diabetes 44(9):1021e1028.an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
[34] Nanto-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T.,
Hekkala, A., et al., 2008. Nasal insulin to prevent type 1 diabetes in
children with HLA genotypes and autoantibodies conferring increased risk
of disease: a double-blind, randomised controlled trial. Lancet 372(9651):
1746e1755.
[35] Gale, E.A., Bingley, P.J., Emmett, C.L., Collier, T., European Nicotinamide
Diabetes Intervention Trial Group, 2004. European nicotinamide diabetes
intervention trial (ENDIT): a randomised controlled trial of intervention before
the onset of type 1 diabetes. Lancet 363(9413):925e931.
[36] Bingley, P.J., Gale, E.A., European Nicotinamide Diabetes Intervention Trial
Group, 2006. Progression to type 1 diabetes in islet cell antibody-positive
relatives in the European Nicotinamide Diabetes Intervention Trial: the role
of additional immune, genetic and metabolic markers of risk. Diabetologia
49(5):881e890.
[37] Bingley, P.J., Mahon, J.L., Gale, E.A., European Nicotinamide Diabetes Inter-
vention Trial Group, 2008. Insulin resistance and progression to type 1 dia-
betes in the European nicotinamide diabetes intervention trial (ENDIT).
Diabetes Care 31(1):146e150.
[38] Vandemeulebroucke, E., Gorus, F.K., Decochez, K., Weets, I., Keymeulen, B.,
De Block, C., et al., 2009. Insulin treatment in IA-2A-positive relatives of type 1
diabetic patients. Diabetes & Metabolism 35(4):319e327.
[39] Diabetes Prevention TrialeType 1 Diabetes Study Group, 2002. Effects of
insulin in relatives of patients with type 1 diabetes mellitus. New England
Journal of Medicine 346(22):1685e1691.
[40] Skyler, J.S., Krischer, J.P., Wolfsdorf, J., Cowie, C., Palmer, J.P.,
Greenbaum, C., et al., 2005. Effects of oral insulin in relatives of patients with
type 1 diabetes: the diabetes prevention trialetype 1. Diabetes Care 28(5):
1068e1076.
[41] Chase, H.P., Cuthbertson, D.D., Dolan, L.M., Kaufman, F., Krischer, J.P.,
Schatz, D.A., et al., 2001. First-phase insulin release during the intravenous
glucose tolerance test as a risk factor for type 1 diabetes. The Journal of
Pediatrics 138(2):244e249.
[42] Sosenko, J.M., Skyler, J.S., Herold, K.C., Palmer, J.P., Type 1 Diabetes
TrialNet, Diabetes Prevention Trial-Type 1 Study Group, 2012. The metabolic
progression to type 1 diabetes as indicated by serial oral glucose tolerance
testing in the diabetes prevention trial-type 1. Diabetes 61(6):1331e1337.
[43] Sosenko, J.M., Palmer, J.P., Rafkin-Mervis, L., Krischer, J.P., Cuthbertson, D.,
Matheson, D., et al., 2008. Glucose and C-peptide changes in the perionset
period of type 1 diabetes in the diabetes prevention Trial-Type 1. Diabetes
Care 31(11):2188e2192.
[44] Sosenko, J.M., Palmer, J.P., Rafkin, L.E., Krischer, J.P., Cuthbertson, D.,
Greenbaum, C.J., et al., 2010. Trends of earlier and later responses of C-
peptide to oral glucose challenges with progression to type 1 diabetes in
diabetes prevention trial-type 1 participants. Diabetes Care 33(3):620e625.
[45] Sosenko, J.M., Palmer, J.P., Rafkin-Mervis, L., Krischer, J.P., Cuthbertson, D.,
Mahon, J., et al., 2009. Incident dysglycemia and progression to type 1 dia-
betes among participants in the diabetes prevention trial-type 1. Diabetes Care
32(9):1603e1607.
[46] Ferrannini, E., Mari, A., Nofrate, V., Sosenko, J.M., Skyler, J.S., DPT-1 Study
Group, 2010. Progression to diabetes in relatives of type 1 diabetic patients:
mechanisms and mode of onset. Diabetes 59(3):679e685.
[47] Mahon, J.L., Sosenko, J.M., Rafkin-Mervis, L., Krause-Steinrauf, H.,
Lachin, J.M., Thompson, C., et al., 2009. The TrialNet natural history study of
the development of type 1 diabetes: objectives, design, and initial results.
Pediatric Diabetes 10(2):97e104.
[48] Sosenko, J.M., Krischer, J.P., Palmer, J.P., Mahon, J., Cowie, C.,
Greenbaum, C.J., et al., 2008. A risk score for type 1 diabetes derived from
autoantibody-positive participants in the diabetes prevention trial-type 1.
Diabetes Care 31(3):528e533.
[49] Sosenko, J.M., Skyler, J.S., Mahon, J., Krischer, J.P., Beam, C.A.,
Boulware, D.C., et al., 2011. Validation of the diabetes prevention trial-type 1MOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comrisk score in the TrialNet natural history study. Diabetes Care 34(8):1785e
1787.
[50] Sosenko, J.M., Skyler, J.S., Mahon, J., Krischer, J.P., Beam, C.A.,
Boulware, D.C., et al., 2012. The application of the diabetes prevention trial-
type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes
Care 35(7):1552e1555.
[51] Nathan, B.M., Boulware, D., Geyer, S., Atkinson, M.A., Colman, P., Goland, R.,
et al., 2017. Dysglycemia and Index60 as prediagnostic end points for type 1
diabetes prevention trials. Diabetes Care 40(11):1494e1499.
[52] Sosenko, J.M., Skyler, J.S., DiMeglio, L.A., Beam, C.A., Krischer, J.P.,
Greenbaum, C.J., et al., 2015. A new approach for diagnosing type 1 diabetes
in autoantibody-positive individuals based on prediction and natural history.
Diabetes Care 38(2):271e276.
[53] Sosenko, J.M., Skyler, J.S., Mahon, J., Krischer, J.P., Greenbaum, C.J.,
Rafkin, L.E., et al., 2014. Use of the diabetes prevention trial-type 1 risk score
(DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.
Diabetes Care 37(4):979e984.
[54] Herold, K.C., Usmani-Brown, S., Ghazi, T., Lebastchi, J., Beam, C.A.,
Bellin, M.D., et al., 2015. Beta cell death and dysfunction during type 1 dia-
betes development in at-risk individuals. Journal of Clinical Investigation
125(3):1163e1173.
[55] Ismail, H.M., Xu, P., Libman, I.M., Becker, D.J., Marks, J.B., Skyler, J.S., et al.,
2018. The shape of the glucose concentration curve during an oral glucose
tolerance test predicts risk for type 1 diabetes. Diabetologia 61(1):84e92.
[56] Sims, E.K., Evans-Molina, C., Tersey, S.A., Eizirik, D.L., Mirmira, R.G., 2018.
Biomarkers of islet beta cell stress and death in type 1 diabetes. Diabetologia
61(11):2259e2265.
[57] Tersey, S.A., Nishiki, Y., Templin, A.T., Cabrera, S.M., Stull, N.D., Colvin, S.C.,
et al., 2012. Islet beta-cell endoplasmic reticulum stress precedes the onset of
type 1 diabetes in the nonobese diabetic mouse model. Diabetes 61(4):818e
827.
[58] Rodriguez-Calvo, T., Zapardiel-Gonzalo, J., Amirian, N., Castillo, E.,
Lajevardi, Y., Krogvold, L., et al., 2017. Increase in pancreatic proinsulin and
preservation of beta-cell mass in autoantibody-positive donors prior to type 1
diabetes onset. Diabetes 66(5):1334e1345.
[59] Eizirik, D.L., Miani, M., Cardozo, A.K., 2013. Signalling danger: endoplasmic
reticulum stress and the unfolded protein response in pancreatic islet
inflammation. Diabetologia 56(2):234e241.
[60] Cianciaruso, C., Phelps, E.A., Pasquier, M., Hamelin, R., Demurtas, D.,
Alibashe Ahmed, M., et al., 2017. Primary human and rat beta-cells release
the intracellular autoantigens GAD65, IA-2, and proinsulin in exosomes
together with cytokine-induced enhancers of immunity. Diabetes 66(2):
460e473.
[61] Roder, M.E., Knip, M., Hartling, S.G., Karjalainen, J., Akerblom, H.K.,
Binder, C., 1994. Disproportionately elevated proinsulin levels precede the
onset of insulin-dependent diabetes mellitus in siblings with low first phase
insulin responses. The Childhood Diabetes in Finland study group. The Journal
of Cinical Endocrinology and Metabolism 79(6):1570e1575.
[62] Truyen, I., De Pauw, P., Jorgensen, P.N., Van Schravendijk, C., Ubani, O.,
Decochez, K., et al., 2005. Proinsulin levels and the proinsulin:c-peptide ratio
complement autoantibody measurement for predicting type 1 diabetes. Dia-
betologia 48(11):2322e2329.
[63] Van Dalem, A., Demeester, S., Balti, E.V., Keymeulen, B., Gillard, P.,
Lapauw, B., et al., 2016. Prediction of impending type 1 diabetes through
automated dual-label measurement of proinsulin:C-peptide ratio. Public Li-
brary of Science one 11(12):e0166702.
[64] Sims, E.K., Chaudhry, Z., Watkins, R., Syed, F., Blum, J., Ouyang, F., et al.,
2016. Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the
onset of type 1 diabetes. Diabetes Care 39(9):1519e1526.
[65] Keskinen, P., Korhonen, S., Kupila, A., Veijola, R., Erkkila, S.,
Savolainen, H., et al., 2002. First-phase insulin response in young healthyccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). S137
Reviewchildren at genetic and immunological risk for Type I diabetes. Diabetologia
45(12):1639e1648.
[66] Evans-Molina, C., Sims, E.K., DiMeglio, L.A., Ismail, H.M., Steck, A.K.,
Palmer, J.P., et al., 2018. Beta Cell dysfunction exists more than 5 years before
type 1 diabetes diagnosis. Journal of clinical investigation insight 3(15):e120877.
[67] Rosenbloom, A.L., Bianchi, R., Chin, F.T., 1973. Screening for glucose intol-
erance in siblings of children with diabetes. Metabolism 22(2):351e354.
[68] Orchard, T., Wagener, D., Rabin, B., LaPorte, R., Cavender, D., Kuller, L., et al.,
1986. Glucose tolerance in siblings of Type 1 diabetic patients relationship to
HLA status. Diabetologia 29(1):39e45.
[69] Vialettes, B., Mattei-Zevaco, C., Badier, C., Ramahandridona, G., Lassmann-
Vague, V., Vague, P., 1988. Low acute insulin response to intravenous
glucose. A sensitive but non-specific marker of early stages of Type 1 (insulin-
dependent) diabetes. Diabetologia 31(8):592e596.
[70] Carel, J., Boitard, C., Bougneres, P., 1993. Decreased insulin response to
glucose in islet cell antibody-negative siblings of type 1 diabetic children.
Journal of Clinical Investigation 92(1):509.
[71] Johansen, K., Soeldner, J.S., Gleason, R.E., Gottlieb, M.S., Park, B.N.,
Kaufmann, R.L., et al., 1975. Serum insulin and growth hormone response
patterns in monozygotic twin siblings of patients with juvenile-onset diabetes.
New England Journal of Medicine 293(2):57e61.
[72] Schober, E., Schernthaner, G., Frisch, H., Bieber, J., Mayr, W., 1983. Beta cell
function in siblings of diabetic children and HLA type. Archives of Disease in
Childhood 58(11):923e925.
[73] Hollander, P.H., Asplin, C.M., Kniaz, D., Hansen, J.A., Palmer, J.P., 1982.
Beta-cell dysfunction in nondiabetic HLA identical siblings of insulin-dependent
diabetics. Diabetes 31(2):149e153.
[74] Ginsberg-Fellner, F., Dobersen, M.J., Witt, M.E., Rayfield, E.J., Rubinstein, P.,
Notkins, A.L., 1982. HLA antigens, cytoplasmic islet cell antibodies, and
carbohydrate tolerance in families of children with insulin-dependent diabetes
mellitus. Diabetes 31(4 Pt 1):292e298.
[75] Johnston, C., Raghu, P., McCulloch, D.K., Beard, J.C., Ward, W.K., Klaff, L.J.,
et al., 1987. Beta-cell function and insulin sensitivity in nondiabetic HLA-
identical siblings of insulin-dependent diabetics. Diabetes 36(7):829e837.
[76] Hartling, S.G., Lindgren, F., Dahlqvist, G., Persson, B., Binder, C., 1989.
Elevated proinsulin in healthy siblings of IDDM patients independent of HLA
identity. Diabetes 38(10):1271e1274.
[77] Lindgren, F., Dahlquist, G., Efendic, S., Moller, E., Persson, B., Thalme, B.,
et al., 1987. Glucose-induced insulin response and insulin sensitivity is not
related to HLA-type but to age in young siblings of type 1 (insulin-dependent)
diabetic patients. Diabetologia 30(9):727e732.
[78] Ma, X., Becker, D., Arena, V.C., Vicini, P., Greenbaum, C., 2009. The effect of
age on insulin sensitivity and insulin secretion in first-degree relatives of type 1
diabetic patients: a population analysis. The Journal of Cinical Endocrinology
and Metabolism 94(7):2446e2451.
[79] Heaton, D.A., Millward, B.A., Gray, P., Tun, Y., Hales, C.N., Pyke, D.A., et al., 1987.
Evidence of beta cell dysfunction which does not lead on to diabetes: a study of
identical twins of insulin dependent diabetics. BMJ 294(6565):145e146.S138 MOLECULAR METABOLISM 27 (2019) S129eS138  2019 Published by Elsevier GmbH. This is[80] Heaton, D., Millward, B., Gray, I., Tun, Y., Hales, C., Pyke, D., et al., 1988.
Increased proinsulin levels as an early indicator of B-cell dysfunction in non-
diabetic twins of type 1 (insulin-dependent) diabetic patients. Diabetologia
31(3):182e184.
[81] Lindgren, F., Hartling, S., Dahlquist, G., Binder, C., Efendic, S., Persson, B.,
1991. Glucose-induced insulin response is reduced and proinsulin response
increased in healthy siblings of type 1 diabetic patients. Diabetic Medicine
8(7):638e643.
[82] Spinas, G.A., Snorgaard, O., Hartling, S.G., Oberholzer, M., Berger, W., 1992.
Elevated proinsulin levels related to islet cell antibodies in first-degree relatives
of IDDM patients. Diabetes Care 15(5):632e637.
[83] Campbell-Thompson, M.L., Filipp, S.L., Grajo, J.R., Nambam, B., Beegle, R.,
Middlebrooks, E.H., et al., 2019. Relative pancreas volume is reduced in first-
degree relatives of patients with type 1 diabetes. Diabetes Care 42(2):281e
287.
[84] Insel, R.A., Dunne, J.L., Atkinson, M.A., Chiang, J.L., Dabelea, D.,
Gottlieb, P.A., et al., 2015. Staging presymptomatic type 1 diabetes: a sci-
entific statement of JDRF, the Endocrine Society, and the American Diabetes
Association. Diabetes Care 38(10):1964e1974.
[85] Eizirik, D.L., Sammeth, M., Bouckenooghe, T., Bottu, G., Sisino, G., Igoillo-
Esteve, M., et al., 2012. The human pancreatic islet transcriptome: expression
of candidate genes for type 1 diabetes and the impact of pro-inflammatory
cytokines. Public Library of Science Genetics 8(3):e1002552.
[86] Marroqui, L., Dos Santos, R.S., Floyel, T., Grieco, F.A., Santin, I., Op de
Beeck, A., et al., 2015. TYK2, a candidate gene for type 1 diabetes, modulates
apoptosis and the innate immune response in human pancreatic beta-cells.
Diabetes 64(11):3808e3817.
[87] Dos Santos, R.S., Marroqui, L., Velayos, T., Olazagoitia-Garmendia, A., Jaur-
egi-Miguel, A., Castellanos-Rubio, A., et al., 2019. DEXI, a candidate gene for
type 1 diabetes, modulates rat and human pancreatic beta cell inflammation
via regulation of the type I IFN/STAT signalling pathway. Diabetologia 62(3):
459e472.
[88] Redondo, M.J., Geyer, S., Steck, A.K., Sosenko, J., Anderson, M., Antinozzi, P.,
et al., 2018. TCF7L2 genetic variants contribute to phenotypic heterogeneity of
type 1 diabetes. Diabetes Care 41(2):311e317.
[89] Redondo, M.J., Muniz, J., Rodriguez, L.M., Iyer, D., Vaziri-Sani, F.,
Haymond, M.W., et al., 2014. Association of TCF7L2 variation with single islet
autoantibody expression in children with type 1 diabetes. BMJ Open Diabetes
Research Care 2(1):e000008.
[90] Williams, A.J., Bingley, P.J., Moore, W.P., Gale, E.A., ENDIT Screening Group,
European Nicotinamide Diabetes Intervention Trial, 2002. Islet autoantibodies,
nationality and gender: a multinational screening study in first-degree relatives
of patients with Type I diabetes. Diabetologia 45(2):217e223.
[91] Atkinson, M.A., von Herrath, M., Powers, A.C., Clare-Salzler, M., 2015. Current
concepts on the pathogenesis of type 1 diabeteseconsiderations for attempts
to prevent and reverse the disease. Diabetes Care 38(6):979e988.an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
